Mikhail Blagosklonny: Providing Insight in Cancer and Aging Discipline

Great strides have been taken the field in the advancement of the medical sector. With the use of the modern technology, the scientists and Doctors have improved the quality medication. One department that has significantly benefited has been the Cancer sector. Significant developments are being done, and now we can dare to dream of a cancer-free world.

Scientists have developed and are still researching and developing new treatments for a variety cancer condition. One of the researches being done is on the TOR Signaling in Aging and Cancer. Mikhail Blagosklonny has drawn up this hypothesis. The hypothesis will be tested using the Rapamycin. Read more on Impact Journals.

Rapamycin is cancer drug used by many patients. The drug also other functions as it act as an immunosuppressant. It works in preventing the human body from rejecting a transplant especially the kidney transplants. The drug is successful in fighting cancer but has also been used to aid in life extension.

Mikhail is a scientist who has done research on Cancer and aging. He is also involved in research on cancer and cancer therapies. He is specifically interested in the treatment that protects the cells from damage. He has built a reputable career through his different research projects. Mikhail is a passionate advocate for the Rapamycin and its role in life extension.

Mikhail Blagosklonny earned his M.D in internal medicine from the First Pavlov State Medical University of St. Petersburg. Soon after, he decided to pursue his Ph.D. in experimental medicine and Cardiology from the same University. Mikhail academic career started when he joined the New York Medical College as the associate professor of medicine. He later took the position of senior scientist at the Ordway Research Institute. He is the professor of Oncology at the Roswell Park Cancer Institute.

Mikhail has participated in different editorial activities. He is the Editor-in-Chief of Aging, Cell Cycle, and Oncotarget. He is a member of the editorial board of Cell and Differentiation Journal. Mikhail serves as the associate editor of the Cancer Biology and Therapy. View Mikhail’s profile on Google Scholar

Mikhail has published 270 peer-reviewed journals on several publication sites.